rheumatoid arthritis is chronic inflammatory disease having symmetrical pattern , can affect the small and large joints. cause is unknown but there is + RH factor and there is pannus formation including the cartilage and joint destruction, reduction in synovial fluid,clinical feature includes morning stiffness fatigue, fever. pharmacology treatment and physiotherapy management.
rheumatoid arthritis is chronic inflammatory disease having symmetrical pattern , can affect the small and large joints. cause is unknown but there is + RH factor and there is pannus formation including the cartilage and joint destruction, reduction in synovial fluid,clinical feature includes morning stiffness fatigue, fever. pharmacology treatment and physiotherapy management.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Introduction ,pathogenesis , clinical manifestations of rheumatoid
1. INTRODUCTION ,PATHOGENESIS , CLINICAL
MANIFESTATIONS,CLASSIFICATION, DIAGNOSIS,
DIFFERENTIAL DIAGNOSIS,
COMPLICATIONS & MANAGEMENT
OF RHEUMATOID ARTHRITIS
Dr .Y.Saipramod
2. INTRODUCTION
Definition-
• Chronic inflammatory systemic disease of adults
characterized by destructive and proliferative changes
in synovial membrane , periarticular structures,
skeletal muscle and perineural sheath .
• Eventually leads to joint destruction , deformity and
ankylosis
3. • Historical background-
• Recognised In 1800 by French physician
Dr.Augustine Jacob.
• RA coined by Dr.Alfred Barring
• RA Factor discovered by Billing ,
Cecil and Dawson.
4. Epidemiology
• Prevalence of - 0.8% to 2.1% of the population
• Gender predilection ratio – Women: Men – 3:1
• Prevalence increases with age (40-50yrs)
• About 40-60% have severe disease
• Median life expectancy is shortened by 3 to 7
years
• Onset mostly between ages of 35 – 60 years
5. Aetiology
• Exact etiology is not known
• Family studies indicates a genetic predisposition like
HLA DR4& HLA DR1
• In genetically susceptible host, it may be a
manifestation to an infectious agent like
Mycoplasma, EBV, Rubella virus, parvo virus, CMV.
• Other possible causes would be allergic (
eosinophilia) endocrine (in response to
adrenocortical steroids)
• smoking has been clearly identified risk for RA in
genetically susceptible individuals.
6.
7. PATHOGENESIS
• Most widely accepted theory is immunogenic
resposnse which takes place in synovium.
• The pathogenesis of RA involves a continuous
interaction of many cells, molecules, and
processes.
• B cells have been postulated to play a number
of roles, including autoantibody formation, T-
cell activation, antigen presentation, and
cytokine production.
• In some circumstances, B cells can act as
highly efficient antigen-presenting cells.
8. • Activated T cells, in turn, activate B cells directly
and via proinflammatory mediators.
• Activated B cells differentiate into antibody-
producing plasma cells.
• Both rheumatoid factor (RF) and anticitrullinated
C peptide (anti-CCP) antibodies form immune
complexes that can activate, complement, and
attract other inflammatory cells to the synovium.
• Activated B cells produce a number of
proinflammatory mediators, including IL-6, TNF-
alpha, interferon gamma, and lymphotoxin.
9. • Proinflammatory mediators from T cells and B
cells activate macrophages.
• Macrophages produce IL-6, TNF-alpha, IL-1,
and interferon gamma.
• Dendritic cells produce TNF-alpha, IL-1, and IL-
6, attracting additional cells to the
inflammatory infiltrate in the synovium.
• Macrophages directly secrete matrix
metalloproteases and other proteolytic
enzymes that damage the synovial tissue
10. • Causing inflammation of
the synovium which forms
pannus, a granulomatous
mass( containing
lymphocytes and other
inflammatory substances)
• The pannus grows and
destroys cartilage ,
tendons and ligaments.
• Systemic manifestations of
RA may be due to release
of inflammatory mediators
like IL-1, TNF, & IL-6 from
synovium
13. PATHOLOGY
• JOINTS-
• Synovial joints
• Infiltrated with lymphocytes, plasma cells, and
macrophages .
• Pannus formation
• This replaces the articular cartilage with
fibrous connective tissue.
• Fibrous ankylosis
• Undergoes metaplasia to form bony ankylosis.
14. • MUSCLES-
• Nodular Polymyositis
• Degeneration of individual muscle fibre and
replaced by fibrous tissue
• Causing deformities and restriction of
movements.
15. • SUBCUTANEOUS NODULES-
• It is a basic rheumatoid unit with a
central fibrionid necrosis consisting
of cellular debris, fragmented
collagen fibres, fibrinous exudate
surrounded by radially arranged
proliferationg mononuclear cells
• Outer dense connective tissues with
marked round cell infiltrate.
• These are found over pressure
points like elbow , tibia.
• Similar leisions can occur in lungs,
pleura, pericardium, sclera.
16. CLINICAL FEATURES
• Chronic polyarthritis with Insidious onset
• Main symptom include pain & morning stiffness
of > 1hr of peripheral joint.
• Constitutional symptoms include generalized
weakness, fatigue, anorexia, weight loss, rarely
fever.
• Symmetrical pattern of involvement of joints is
more typical of RA.
• Clinically synovial inflammation in affected joint
causes warmth, swelling, tenderness, and
limitation of motion
17. • The affected inflamed joint usually held in a
position of flexion in order to maximize the
joint volume and minimize the distention of
the capsule.
• Later , soft tissue contractures or fibrous or
bony ankylosis leads to fixed defromities.
18. CHARACTERISTIC DEFORMITIES
• Wrist & hand-
• Z-Deformity- radial deviation of wrist and
ulnar deviation of digits often with palmar
subluxation of proximal phalanges
19. • Swan neck deformity- hyperextension of
proximal interphalangeal joints with
compensatory flexion of distal interphalangeal
joints.
• Boutonnires deformity- flexion at proximal
interphalangeal joints and extension of distal
interphalangeal joint.
• Synovitis of wrist can lead to carpal tunnel
syndrome.
20. • Foot-
• Hallux valgus
• Widening of forefoot
• Hammer toes
• Callosity under PIP joint
• Achilles tendinities
21. • Elbow- leads to swelling , limitation of
movements ,flexion contractures.
• Knee joint- synovial hypertrophy , chronic
effusion , ligamentous laxity . Chronic effusion
leads to bakers cyst.
• Hip joint – may cause erosion and remodelling of
acetabulum leading to protrusio acetabulum.
• Neck- inflammation of synovial joints of upper
cervical spine leads to atlanto axial subluxation
and presents as pain in occiput
22. • Rheumatoid nodule-
occurs in 20-30% of
patients with RA .
Usually on periarticular
structures, extensor
surfaces, and areas of
mechanical pressure like
proximal ulna, olecranon
bursa, achillis tendon
and occiput.
23. • Rheumatoid vasculitis- it can cause
polyneuropathy, mononeuritis multiplex,
cutaneous ulceration, dermal necrosis. Digital
necrosis and visceral infarction.
• Pleuro pulmonay manifestations- interstitial
fibrosis, pleuro pulmonary nodules ,
pneumonitis and arteritis.
• Cardiac- pericarditis , MI and aortitis
• Musculo skeletal- muscle wasting,
Tenosynovitis, bursitis and osteoporosis.
26. CLASSIFICATION
Progression of rheumatoid arthritis classified in
to 4 stages based on CLINICAL & RADIOLOGICAL
Findings.ACR
Stage 1 (early RA)
• No destructive changes +/- evidence of
osteoporosis
stage II (moderate progression)
• Limited Joint mobility with no joint deformities
• Adjacent muscle atrophy
• Extra-articular soft tissue lesions
• periarticular osteoporosis with or without
subchondral bone destruction.
27. Stage III (severe progression)
• Joint deformity (eg, subluxation, ulnar deviation,
hyperextension) without fibrous or bony ankylosis
• Extensive muscle atrophy
• Extra-articular soft tissue lesions (eg, nodules,
tenosynovitis)
• Radiographic evidence of cartilage and bone
destruction in addition to periarticular
osteoporosis
Stage IV (terminal progression)
• Fibrous or bony ankylosis
28. DIAGNOSIS
X-rays
Early on, x-rays show only the
features of synovitis: soft-tissue
swelling and peri-articular
osteoporosis.
The later stages are marked by
the appearance of marginal
bony erosions and narrowing of
the articular space, especially in
the proximal joints of the hands
and feet.
However, most individuals have
evidence of erosions within 2
years.
29. • In advanced
disease,articular
destruction and joint
deformity are obvious.
• Flexion and extension
views of the cervical spine
often show subluxation at
the atlanto-axial or mid-
cervical levels
30. Blood investigations
• Normocytic, hypochromic anaemia.
• In active phases the ESR and CRP concentration are
usually raised.
Serological tests:
-Rheumatoid factor(Auto antibody against Fc portion
of IgG)positive in about 80 per cent of patients
-antinuclear factors are present in 30 per cent.
• Neither of these tests is specific and neither is required
for a diagnosis of rheumatoid arthritis.
• Tests such as those for anti-CCP antibodies have added
much greater specificity but at the expense of
sensitivity.
31. Synovial biopsy
• Synovial tissue may be obtained by needle biopsy,
via the arthroscope, or by open operation.
• Unfortunately, most of the histological features of
rheumatoid arthritis are non-specific.
32. The “OLD” American College of Rheumatology (ACR)
criteria for the diagnosis of Rheumatoid arthritis 7
1. Morning stiffness
2. Arthritis of 3 or more joint areas, observed by a physician.
3. Arthritis of hand and wrist joints
4. Symmetric arthritis
5. Rheumatoid nodule
6. Serum Rheumatoid Factor
7. Radiographic changes hand and wrist radiographs--erosions
or juxta-articular osteopenia
• 1-4 MUST BE PRESENT ATLEAST FOR 6 WKS
33. NEW ACR Eular Criteria for RA 4 Domains
• 1. Domain: Joint involvement – max 5points
• 2. Domain: Serology -max 3points
• 3. Domain: Duration of synovitis- max 1point
• 4. Domain: Acute phase reactants -max 1point
• YOU NEED 6 points for a DEFINITE RA DIAGNOSIS
34. Domain: Joint involvement
– 1 medium-large joint (0 points)
– 2-10 medium-large joints (1 point)
– 1-3 small joints (2 points)
– 4-10 small joints (3 points)
– More than 10 small joints (5 points)
Note: Patients receive the highest point level
they fulfill within each domain. For example, a
patient with five small joints involved and four
large joints involved scores 3 points.
35. Domain: Serology -max 3points
-No RF or anti-CCP (0 points)
• – One positive at low titer, < 3x normal
(2 points)
• – One positive at high titer, > 3x normal
(3 points)
36. Domain: Acute phase reactants
• Neither (CRP) nor (ESR) is abnormal (0 points)
• –Abnormal CRP or abnormal ESR (1 point)
37. Domain: Duration of synovitis- max 1point
• < 6 weeks (0 points)
• >6 weeks or longer (1 point)
38. Symmetric joint disease is not a feature of new criteria.
Classic radiographic changes such as marginal erosions
automatically qualify patients for RA classification if they have a
single swollen joint.
Imaging evidence of synovitis, including ultrasound or MRI, can
be used to classify patients even in the absence of symptoms
if patients have high titers of RF or Anti citrulinated peptide
Antibody and elevated acute phase reactants
Joint fluid is straw-colored, is slightly cloudy, and contains many
flecks of fibrin and 5000 to 25,000 whiteblood cells/mm3; at least
50% of these are polymorphonuclear leukocytes.
39. Differential diagnosis
• Psoriatic arthritis
• nail changes and skin symptoms
• Reactive arthritis
asymmetrically involves heel, sacroiliac joints and large joints of the
leg. It is usually associated with urethritis, conjunctivitis, iritis,
painless buccal ulcers..
• Ankylosing spondylitis
• This mainly involves the spine
• Gout & Pseudo gout
• usually involves particular joints (knee, MTP1, heels) and can be
distinguished with an aspiration of joint fluid if in doubt. Redness,
asymmetric distribution of affected joints, pain occurs at night and
the starting pain is less than an hour with gout.
40. • Lyme disease
• causes erosive arthritis and may closely resemble
RA – it may be distinguished by blood test in
endemic areas
• Polyarticular osteoarthritis (OA).
• Distinguished with X-rays of the affected joints
and blood tests, older age, starting pain less than
an hour, asymmetric distribution of affected
joints and pain worsens when using joint for
longer periods
• Viral arthritis.
42. MANAGEMENT :-
AIMS :
1.Relief of inflammation and pain.
2.Correction and control of systemic
manifestations.
3.Prevention of deformity
4.Correction of existing deformity.
5.Improvement of functional capacity
43. Supportive measures :
-Patient education :
Provide basic information about disease ,treatment
and importance of follow up.
-Behavioural modification :
Importance of rest, Exercise, and Proper nutrition
-Splints – These have 3 main function.
Rest and relief of pain.
Prevention and correction of deformity.
Fixation of damaged joint in good functional positions
-Physio therapy : various forms of local heating and cooling
used to reduce muscle spasm .
44. Drug therapy:
1. Non steroidal anti inflammatory drugs (NSAID’S)
NSAIDS reduce the signs and symptoms of inflammation but do not
eliminate the underlying cause. Joint damage continues during
administration of NSAIDS .
Mechanism of action :
Effects related to primary action of drugs by inhibitions Arachidonate cyclo
oxygenase (COX). Thus, inhibits the production of prostaglandins and
thromboxanes which mediate inflammation and other effects.
Drugs are:-
• Aspirin, Indomethacin ,Piroxicam, Tolmetin, (cox-1)
• Ibuprofen, Neproxen, Diclofenac, ketoprofen,( non selective)
• Nimusulide, Etoricoxib, Meloxicab, Rofecoxib,etc (cox-2)
Adverse effects;
Nausea, vomiting, Gastric damage, ulceration, and perforation, Skin reaction, Analgesic
associated nephropathy, Liver disorders etc
45. 2. Systemic Glucocorticoids :
one of the most effective treatment in providing symptomatic relief
in rheumatoid arthritis.
Mechanism of action :- It inhibits the synthesis prostaglandins.
It also inhibits TNF- , IL –1 and other proinflammatory mediators.
Dose :- Low dose (<7.5mg/d) prednisolone has been advocated to
control symptoms.
Efficacy :
It provides only symptomatic relief.. They do
not arrest the rheumatoid process nor prevent bone
erosions
46. Intra articular injection of steroids :
Mechanism of action : is similar to that of systemic steroids .
It increases the viscosity and haluronate concentration of
synovial fluid.
Efficacy : Most patients benefit from intraarticular steroids but
the effect last for few days.
Hydrocortisone - Few days to a week
Prednisolone - two weeks or more
Triamcilone- for longer periods
If one or two injection prove ineffective then discontinue
the drug.
47. 3.DMARDS (Disease modifying anti rheumatoid
drugs);
These drugs are known to alter the disease activity in RA.
They exert minimal non specific anti-inflammatory effects,
therefore NSAIDS must be continued during their
administration.
Appearance of benefit from DMARD therapy is usually
delayed for weeks or months.
Decreases C-reactive protein, and ESR and retard the
development of bone erosions.
Recent trend is to start DMARD, especially methotrexate early
in the disease activity.
49. Chloroquine and hydroxycholoquine : - Antimalarial
drugs, found to induce upto 50% remission.
-Acts by reducing monocyte interluken-1 consequntly
inhibiting ‘B’ lymphocytes, so antigen processing may be
interfered.
Dose – Hydroxy choloroquine,400mg/day for 4-6 weeks
followed by 200-400 mg/day for maintainance (Tab
HCQS)
Adverse effect : Retinal Damage, corneal opacity, Graying
of hair, Irritable bowel syndrome, Myopathy and
neuropathy.
50. Sulfa salazine : Has anti-inflammatory activity and primarily
used in ulcerative colitis,
Acts by suppressing the superoxide radicals and cytokines
0f inflammatory cells.
Used in mild/early case.
Dose 1-3 gm/day in 2-3 devided doses.
(sazo en-500mg)
Chlorambucil ;-
It is effective but at the cost of substantial toxicity.
Rarely used specially in cases with secondary
Amylodosis.
dose 2-6 mg/day(Tab Leukerin 2mg,5mg) .
51. Methotrexate :
First DMARD’s of choice, it is an anticancer drug employed for use in
rheumatoid arthritis.
Mechanism of action :
acts by, inhibiting amino imidazine carboxamide (AILAR)
transformylase and thimidalate syntatase with secondary effect on
polymorpho nuclear chemotaxis.
Some effects on dihydro folate reductase and this effects
lymphocyte and macrophage function.
It also inhibits interleukin-1 activity.
Dose and Drug administration :-
-Low dose methotrexate is used in rheumatoid arthritis.
-High dose methotrexate is used an anticancer therapy.
- In rheumatoid arthritis the initial dose of methotrexate is
7.5mg/week, but the dose may be increased upto 20 mg/week
provided there is no toxicity.
-(Tab Altrex,Folitrex,Biotrexate as 2.5mg,5mg,7.5mg )
52. Adverse effects : Diarrhea, alopecia, hematological
toxicity including leucopenia, thrombocytopenia ,
renal failure, acute and chronic pulmonary toxicity.
It causes hepatic fibrosis leading to-Elevation of liver
enzymes and decrease serum albumin.
Use of Folic acid(1mg/day) reduces the Methotrexate toxicity.
Azathioprine;-
It is purine anti metabolite,
- acts by suppressing the cell mediated immunity,
- Given along with steroids because it has steroid sparing effect
-Usually used in cases with systemic manifestation,
Dose 50-150 mg/day. (Tab Azimune, Azoprine,Zymurine 50mg)
53. Cyclo sporine;-
Inhibits IL-1 and IL-2 receptor production by regulating gene
transcription and secondarily inhibit macrophage T cell interaction
and T-cell responsiveness.
Effective in RA but its renal toxicity which is accentuated by
NSAID’s preclude it’s routine use. Usually employed in refractory
cases.
Dose 2.5-5 mg/kg/day
Cyclophsophomide;-
• Suppresses T-cell and B-cell function by 30-40%.
• Due to more toxic reserved for cases with severe systemic
manifestation like necrotising vasculitis Dose 50-100mg/day
(Tab cycloxin, Ledoxen,50mg)
54. Leflunomide :
was approved in 1948 for treatment RA. Is a synthetic isoxazole derivative
with immunosuppressive and antiproliferative properties.
Mechanism of action : It inhibits dihydro orate dehydrogenase – decreases
pyrimidine synthesis –decresaes lymphocyte proliferation.
Dose :
Loading dose of 100mg daily for three days precedes the maintenance dose
of 10-20mg/day.
(Tab Arava, Tab cleft,Tab Lefumide 10mg,20mg)
The response rate of leflunomide in RA is similar to methotrexate.
It is teratogenic and contraindicated in pregnancy.
55. DMARD combination therapy :
The use of combination of DMARDs when a single DMARD
fails adequately to control RA is now generally accepted by
rheumatologist,
1,Triple DMARD’ therapy with methotraxate, sulasalazine and
Hydroxy chloroquine was more effective than methotrexate
alone or sulfasalazine and hyddroxychloroquine combination.
2,The COBRA regimen with step down combination of high
dose prednisolone (60 mg/day tapering to 7.5 mg after
6weeks and 0mg after 35 weeks.) Methotraxate (7.5
mg/weeks for 46weeks), sulfasalazine (2gm/day) was more
effective.
3,Finnish RA combination therapy:(1993-95) used 4 drugs i.e
Methotrexate, Sulfasalazine, Hydroxychloroquine, and
Prednisolone. Found 37 percent remission.
56. Biologics (Cytokine Therapies Targeting TNF and IL-1)
These modify the biologic response as observed in patho physiologic
inflammation process of RA
Agents :
1.Etanarcept;- Is the 1st TNF inhibitor to be approved for use in RA.
Dose :- 25mg subcuateneous inj twice weekly.(Inj Enbrel 25mg vial)
Efficacy : Most effective drug in RA i.e in refractory disease.
- Combination of etanarecept + methotrexate provide additional benefit.
2. Infliximab;-
-It is chimeric anti TNF monoclonal antibody.
-Combination with methotrexate 7.5mg/week seemed to enhance the clinical
response and improves functional status and quality of life.
Dose : single dose of 10mg/kg body weight at 0,2,,6,10,14 weeks.
.
57. 3 Adalimumab :
is a recombinant human immunoglobulin G1 monoclonal antibody that
it is specific for TNF
Dose – 40mg/week subcutaneous
4 Interleukin –1 Receptor antagonist : (Anakira) ;-
Recombinant human IL-1 Ra has been utilized in several RA trials.
Dose : Clinical responses are dose dependent with greatest response in
highest dose group.
-Given daily doses of 30, 75 or 150mg .
OTHER NEWER DRUGS (UNDER TRIAL) ARE
1-cytotoxic T-lymphocytic antigen 4-immunoglobulin
2-B-lymphocyte depletion therapy with Rituximab
3 IL-6 inhibition with monoclonal antibody
58. OPERATIVE TREATMENT :
Indicated in failure of medical treatment, severe pain,
loss of function and progression of disease
1.Synovectomy-
• relieves pain, and improves function.
• Usually done in knee, elbow and small joints of fingers ,in
addition synovectomy of tendon sheaths i.e flexors and
extensors of fingers should undertaken as a prophylactic
measure.
Indications
• In patients with no or minimal radiological evidance of
erosion,
• In presence of persistent pain and swelling of about 6
months .
59. 2.Radical surgery
under taken to relieve pain, restore function, correct
deformity and provide stability.
FINGER DEFORMITIES
A.Intrinsic plus deformity :
• This is due to contracture of the intrinsic muscles
• flexon of the MCP joint and extension of the
interphalangeal joint.
• The deformity develops in combination with the ulnar
deviation of the fingers.
• Inrinsic tightness can be detected by putting the MCP joint
in hyperextension and passively try to flex the distal inter
phalangeal joint. Which is not possible (Bunnell test)
60. -LittlersTechnique :
• Extensor aponeurosis at level of metacarpophalangeal joint consists of long extensor
tendon,
•transverse fibers (which flex metacarpophalangeal joint), and
•oblique fibers (which extend interphalangeal joint).
•The oblique fibers of the EA is incised at its extensor tendon insertion.
•Transverse fibres are preserved to avoid hyperextension of MCP joint.
61. B. SWAN NECK DEFORMITY
- flexion of DIP joint and hyperextension of PIP
joint with flexion of MCP joint
•The commonest cause being rupture of terminal
extensor and tenosynovitis or rupture of flexors
(FDS) may contribute to PIP hyper extension.
62. NALEBUFF, FELDON AND MILLEDER classification
TYPE 1 :PIP joint flexible in all directions with no intrinsic
tightness
Treated - manipulation.
- Flexor tenodesis (FDS) of PIP joint.
- Fusion of DIP joint and
- reconstruction of retinacular ligament or spiral
oblique ligament
TYPE II : Deformities due to intrinsic muscle tightness.
Treated - intrinsic release + one/more of the above procedures.
63. TYPE III : limited active PIP motion in a finger which rests in the
swan-neck position. The lateral bands are adherent in the dorsal
position preventing flexion.
Treated -joint manipulation, -
mobilization of lateral bands and dorsal skin release.
TYPE IV : Destruction of joint surface and often ankylosis of PIP joint.
Treatment : Best treated with Arthrodesis of PIP joint or in ring and
small fingers with Swanson implant arthroplasty of PIP joints.
64. C. Button hole deformity
/Boutonniere Deformity : -
-characterized by flexion of PIP joint and
hyperextension of the DIP joint.
1.Mild Deformity – Flexion deformity at PIP
joint with lessened ability to fully flex the
distal joint. The deformity is passively
correctable indicating that the lateral bands
have subluxated anteriorly but not
adherent. Normal appearing roentgeogram.
Treatment ; -Specific exercises, -
repositioning of lateral bands.
--Proximal inter phalangeal joint
synovectomy
--Extensor tenotomy over middle phalanx .
65. ii. Moderate Deformity :
-Flexion contracture is about 40degree at the PIP joint and hyper extended
DIP joint.
-The deformity is not passively correctable. Indicating that the lateral bands
are adherent ,
-Roentgenogram shows mild joint destruction.
Treatment :--Central slip reconstruction using the lateral band/tendon graft.--
-MCP joint arthroplasty/fusion.
iii. Fixed deformity :-
-Fixed flexion deformity of the PIP joint as much as 90 degree.
-The capsular structures are contracted and the PIP joint may show
ankylosis. The DIP joint may be fixed in hyperextension
Roentegenogram shows destructive joint changes.
Treatment : Because of joint destruction. Arthroplasty or fusion must be
performed.
66. ULNAR DRIFT/DEVIATION OF FINGERS
As the synovium proliferates at the MCP joint, the radial sagittal fibers
of the extensor hood attenuate allowing finger extensors to subluxate in an
ulnar direction into the cleft between metacarpals.
67. Mild to Moderate ulnar Drift :
• The MCP joints are swollen, flexor and extensor tendons are displaced ulnar
wards.
• However there is absence of severely diseased articular surfaces of
dislocated joints.
Treatment :
a-Intrinsic release
b-Extensor tendon realignment and intrinsic rebalancing i.e transferring
tendons from ulnar side to radial side.
C-MCP joint synovectomy.
Severe ulnar drift and MCP dislocation;-
• severe variety often with dislocation of one or more MCP joint.
• The dislocation will be due to the pull of the long flexor tendons on the
finger in the ulnar direction.
Treatment :-
Function of MCP joint may be improved by arthroplasty.
( Swanson implant arthroplasty )
69. RHEUMATOID WRIST;
• dorsal swelling on the wrist within tendon sheaths of extensor
tendons is one of the earliest sign of disease.
typically extensor carpi ulnaris and extensor digitorum
communis sheaths are involved .
Surgical options are;--
• synovectomy i.e volar or dorsal synovectomy.
• wrist arthrodesis in advanced stage, in bilateral fusion some
prefer one in dorsiflexion other in palmar flexion.
• Wrist arthroplasty; two types
1. resection arthroplasty (palmarshelf arthroplasty)
2. implant arthroplasty.(swanson silicone)
71. Thank you
• References-
• TUREK text book of orthopaedics
• Kelly text book of Rheumatology
• Campbell operative orthopaedics
• Harrisons textbook of internal medicine
• Internet.